FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for ...

Related Keywords

Japan ,South Korea ,Singapore ,Garret Hampton ,J Thorac Oncolo ,Unity Lab Services ,Janssen Biotech Inc ,Ministry Of Health ,Drug Administration ,Thermo Fisher ,Fisher Scientific ,Thermo Fisher Scientific Inc ,Our Mission ,Oncomine Dx Target Test ,Thermo Fisher Scientific ,Janssen Biotech ,Middle East ,Thermo Scientific ,Applied Biosystems ,Important Safety Information ,International Association ,Lung Cancer ,Lung Cancer Singapore ,Worldwide Virtual ,